Zacks Research Has Bearish Estimate for PLX Q3 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities research analysts at Zacks Research reduced their Q3 2026 earnings estimates for shares of Protalix BioTherapeutics in a research report issued on Thursday, August 13th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings of ($0.05) per share for the quarter, down from their previous forecast of ($0.03). The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics’ Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at $0.19 EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.02 EPS.

Protalix BioTherapeutics Trading Up 0.4%

Shares of NYSE:PLX opened at $2.35 on Thursday. The firm has a market cap of $189.34 million, a price-to-earnings ratio of -18.08 and a beta of 0.02. Protalix BioTherapeutics has a 1 year low of $1.48 and a 1 year high of $3.19. The business has a fifty day simple moving average of $2.31 and a 200 day simple moving average of $2.36.

Hedge Funds Weigh In On Protalix BioTherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in Protalix BioTherapeutics by 932.7% in the first quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock worth $644,000 after acquiring an additional 268,099 shares in the last quarter. NewEdge Advisors LLC acquired a new position in shares of Protalix BioTherapeutics during the 1st quarter worth $39,000. BNP Paribas Financial Markets raised its holdings in Protalix BioTherapeutics by 126.5% during the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock valued at $34,000 after buying an additional 8,498 shares in the last quarter. Bank of America Corp DE raised its holdings in Protalix BioTherapeutics by 364,766.7% during the second quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock valued at $32,000 after buying an additional 21,886 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Protalix BioTherapeutics in the second quarter worth about $543,000. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical?stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost?effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high?quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.